"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC

被引：0
|
作者：
Zheng, Mei-Mei [1 ,2 ]
Wu, Yi-Long [1 ]
机构：
[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 06 Zhongshan Er Rd, Guangzhou 510080, Peoples R China
[2] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 08期
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; GEFITINIB;
D O I：
10.1016/j.jtho.2024.04.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1146 / 1150
页数：5
相关论文
共 50 条
  • [31] Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.
    Lee, Michael Sangmin
    Overman, Michael J.
    Maru, Dipen M.
    Jiang, Zhi-Qin
    Manuel, Shanequa
    Eng, Cathy
    Kee, Bryan K.
    Fogelman, David R.
    Garrett, Chris R.
    Advani, Shailesh M.
    Sanchez, Eduardo Vilar
    Shureiqi, Imad
    Wolff, Robert A.
    Hamilton, Stanley R.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Effects of Sex and Seasonal Climatic Changes on the Risk of Incidence of Anti-EGFR Therapy-Induced Rash in Cancer Patients: A Retrospective Study
    Arai, Takahiro
    Fujita, Yukiyoshi
    Imai, Hisao
    Matsumoto, Hiroe
    Yamazaki, Miho
    Hiruta, Eriko
    Suzuki, Yuka
    Ojima, Hitoshi
    Hosaka, Hisashi
    Minato, Koichi
    Saito, Taeko
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [33] High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease
    Ruzzo, Annamaria
    Graziano, Francesco
    Vincenzi, Bruno
    Canestrari, Emanuele
    Perrone, Giuseppe
    Galluccio, Nadia
    Catalano, Vincenzo
    Loupakis, Fotios
    Rabitti, Carla
    Santini, Daniele
    Tonini, Giuseppe
    Fiorentini, Giammaria
    Rossi, David
    Falcone, Alfredo
    Magnani, Mauro
    ONCOLOGIST, 2012, 17 (06): : 823 - 829
  • [34] Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
    Manceau, Gilles
    Imbeaud, Sandrine
    Thiebaut, Raphaele
    Liebaert, Francois
    Fontaine, Karine
    Rousseau, Francis
    Genin, Berengere
    Le Corre, Delphine
    Didelot, Audrey
    Vincent, Marc
    Bachet, Jean-Baptiste
    Chibaudel, Benoist
    Bouche, Olivier
    Landi, Bruno
    Bibeau, Frederic
    Leroy, Karen
    Penault-Llorca, Frederique
    Van Laethem, Jean-Luc
    Demetter, Pieter
    Tejpar, Sabine
    Rossi, Simona
    Mosakhani, Neda
    Osterlund, Pia
    Ristamaki, Raija
    Sarhadi, Virinder
    Knuutila, Sakari
    Boige, Valerie
    Andre, Thierry
    Laurent-Puig, Pierre
    CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3338 - 3347
  • [35] Bevacizumab and its impact on survival for patients receiving subsequent anti-EGFR therapy: Results from the South Australian metastatic colorectal cancer registry.
    Price, Timothy Jay
    Karapetis, Christos Stelios
    Roy, Amitesh Chandra
    Padbury, Robert
    Maddern, Guy
    Roder, David
    Piantadosi, Cynthia
    Burge, Matthew E.
    Townsend, Amanda Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [36] Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.
    Kotani, Daisuke
    Mondaca, Sebastian
    Parikh, Aparna
    Bando, Hideaki
    Van Seventer, Emily
    Taniguchi, Hiroya
    Yoshino, Takayuki
    Corcoran, Ryan Bruce
    Yaeger, Rona
    Ebi, Hiromichi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [37] Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
    Zwitter, Matjaz
    Stanic, Karmen
    Rajer, Mirjana
    Kern, Izidor
    Vrankar, Martina
    Edelbaher, Natalija
    Kovac, Viljem
    RADIOLOGY AND ONCOLOGY, 2014, 48 (04) : 361 - 368
  • [38] Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
    Marin, J. A.
    Oliva Bernal, M.
    Plana Serrahima, M.
    Ferrer, M.
    Vilarino Quintela, N.
    Vazquez, S.
    Vilajosana, E.
    Lozano, A.
    Nogues, J.
    Mari, A.
    Bermejo, O.
    Mesia Nin, R.
    Taberna Sanz, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 383 - 383
  • [39] Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy
    Yamada, Takeshi
    Matsuda, Akihisa
    Takahashi, Goro
    Iwai, Takuma
    Takeda, Kohki
    Ueda, Kohji
    Kuriyama, Sho
    Koizumi, Michihiro
    Shinji, Seiichi
    Yokoyama, Yasuyuki
    Ohta, Ryo
    Yoshida, Hiroshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1523 - 1532
  • [40] Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy
    Takeshi Yamada
    Akihisa Matsuda
    Goro Takahashi
    Takuma Iwai
    Kohki Takeda
    Kohji Ueda
    Sho Kuriyama
    Michihiro Koizumi
    Seiichi Shinji
    Yasuyuki Yokoyama
    Ryo Ohta
    Hiroshi Yoshida
    International Journal of Clinical Oncology, 2020, 25 : 1523 - 1532
12345